Antifibrotic activity of anisodamine in vivo is associated with changed intrahepatic levels of matrix metalloproteinase-2 and its inhibitor tissue inhibitors of metalloproteinases-2 and transforming growth factor β1 in rats with carbon tetrachloride-induced liver injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 6, 2009, Pages 1070-1076

  Luo, Lin ^b   Zhou, Ailing ^a,b  

^a Medical College Nantong University ^*  (China)

^b NANTONG MEDICAL COLLEGE   (China)

Author keywords

Anisodamine; Liver fibrosis; Matrix metalloproteinase 2 (MMP2); Tissue inhibitor of metalloproteinase 2 (TIMP2); Transforming growth factor 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ANISODAMINE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; HYALURONIC ACID; HYDROXYPROLINE; MALONALDEHYDE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER FIBROSIS; LIVER PROTECTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ZYMOGRAPHY;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; EXTRACELLULAR MATRIX; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALONDIALDEHYDE; MATRIX METALLOPROTEINASE 2; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLANACEOUS ALKALOIDS; STAINING AND LABELING; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 66549109510     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05756.x     Document Type: Article

References (40)

1. Yang KL, Chang WT, Chuang CC et al. Antagonizing TGF-beta induced liver fibrosis by a retinoic acid derivative through regulation of ROS and calcium influx. Biochem. Biophys. Res. Commun. 2008 365 : 484 9.
2. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 2007 22 (Suppl. 1 S79 84.
3. Lee KS. Hepatic fibrogenesis. Korean J. Gastroenterol. 2006 48 : 297 305.
4. Garcíade León Mdel C, Montfort I, Tello Montes E et al. Hepatocyte production of modulators of extracellular liver matrix in normal and cirrhotic rat liver. Exp. Mol. Pathol. 2006 80 : 97 108. (Pubitemid 41828233)
5. Zhang LJ, Zheng WD, Chen YX et al. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 2007 54 : 2092 8.
6. Dranoff JA, Kruglov EA, Abreu-Lanfranco O et al. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl- 2′,4′-disulfonate (PPADS). In Vivo 2007 21 : 957 65.
7. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008 371 : 838 51.
8. Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J. Appl. Toxicol. 2007 27 : 116 21.
9. Lin LUO, Ailing Z, Daorong J et al. Protective effects and mechanisms of anisodamine on experimental liver injury. J. Chinese Physician 2003 5 : 1193 96.
10. Xingliu W, Xingbang Z. Study on the therapeutic effects and prognosis of anisodamine on chronic active hepatitis B. Acta Academiae Medicinae Suzhou 1999 19 : 1237 46.
11. Liu Y, Liu P, Liu CH et al. Proteomic analysis of proliferation and apoptosis in carbon tetrachloride induced rat liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2005 13 : 563 6.
12. 2± ATPase by hydrogen peroxide in pulmonary vascular smooth muscle plasma membrane. J. Biosci. 2003 28 : 205 13.
13. Lee GP, Jeong WI, Jeong DH et al. Diagnostic evaluation of carbon tetrachloride-induced rat hepatic cirrhosis model. Anticancer Res 2005 25 : 1029 38.
14. Khorshid HR, Azonov JA, Novitsky YA et al. Hepatoprotective effects of setarud against carbon tetrachloride- induced liver injury in rats. Indian J. Gastroenterol. 2008 27 : 110 12.
15. 4-induced liver injury and fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2007 293 : G631 9.
16. Chuan-Tao T, Jin-Sheng G, Manner W et al. Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. J. Gastroenterol. Hepatol. 2007 22 : 877 84.
17. Ibañez P, Solis N, Pizarro M et al. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2007 22 : 846 51.
18. Hsu Y-C, Chiu Y-T, Cheng C-C et al. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J. Gastroenterol. Hepatol. 2007 22 : 99 111. (Pubitemid 44953424)
19. Salunga TL, Cui ZG, Shimoda S. Oxidative stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J. Autoimmun. 2007 29 : 78 86. (Pubitemid 47385107)
20. De Minicis S, Brenner DA. NOX in liver fibrosis. Arch. Biochem. Biophys. 2007 462 : 266 72.
21. Wynn TA. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008 214 : 199 210.
22. Kuriyama S, Yokoyama F, Inoue H et al. Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model. Int. J. Mol. Med. 2007 19 : 317 24.
23. Sugino H, Kumagai N, Watanabe S et al. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2008 19.
24. Knittel T, Janneck T, Muller T. Transforming growth factor betal regulated gene expression of Ito cells. Hepatology 1996 24 : 35.
25. Yoshida M, Nishikawa Y, Omori Y et al. Involvement of signaling of VEGF and TGF-beta in differentiation of sinusoidal endothelial cells during culture of fetal rat liver cells. Cell Tissue Res. 2007 329 : 273 82.
26. Zhao W-L, Jiang Q-J, Tao F-S. Effect of Ani on proliferation of rat hepatic satellate cell. Heilingjiang Med. Pharm. 2004 27 : 32 3.
27. Theret N, Musso O, L'Helgoualc'h A. et al. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am. J. Pathol. 1997 150 : 51 8.
28. Díaz-Gil JJ, García-Monzón C, Rúa C et al. The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats. Histol. Histopathol. 2008 23 : 583 91.
29. Han YP. Matrix metalloproteinases, the pros and cons, in liver fibrosis. J. Gastroenterol. Hepatol. 2006 21 (Suppl. 3 S88 91.
30. Wang XB, Liu P, Tang ZP et al. The role of changes of MMP-2, 9 activity in the development of liver fibrosis in rats. Zhonghua Gan Zang Bing Za Zhi 2004 12 : 267 70.
31. Rojkind M, Greenwel P. Pathophysiology of liver fibrosis. In : Arias IM, Boyer JL, Chisari FV, Fausto N, Schachter D, Shafritz DA, eds. The Liver: Biology and PathoBiology, 4th edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2001 721 38.
32. Knittel T, Mehde M, Kobold D et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta 1. J. Hepatol. 1999 30 : 48 60. (Pubitemid 29023652)
33. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-ß signaling pathway in hepatic fibrosis. Liver Int. 2006 26 : 8 22.
34. Verrecchia F, Chu M L, Mauviel A. Identification of novel TGF-b/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 2001 276 : 17058 62.
35. Yoshiji H, Kuriyama S, Miyamoto Y et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000 32 : 1248 54.
36. Hu YB, Li DG, Lu HM. Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats. J. Gene Med. 2007 9 : 217 29.
37. Sentíes-Gómez MD, Gálvez-Gastélum FJ, Meza-García E et al. Hepatic fibrosis: role of matrix metalloproteases and TGF beta. Gac. Med. Mex. 2005 141 : 315 22.
38. Xie Yumei, Nie Q. New hot spot of liver fibrosis therapy-TIMPs. Shi Jie Hua Ren Xiao Hua Za Zhi 2003 11 : 601 5.
39. Fleischmajer R, Kuroda K, Hazan R et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J. Invest. Dermatol. 2000 115 : 771 7.
40. Garciade León Mdel C, Montfort I, Tello Montes E et al. Hepatocyte production of modulators of extracellular liver matrix in normal and cirrhotic rat liver. Exp. Mol. Pathol. 2006 80 : 97 108. (Pubitemid 41828233)